Pioglitazone Prevents Hypertension and Reduces Oxidative Stress in Diet-Induced Obesity

Hypertension

Volumn 43, Issue 1, 2004, Pages 48-56

  Dobrian, Anca D ^a   Schriver, Suzanne D ^a   Khraibi, Ali A ^a   Prewitt, Russell L ^a  

^a EASTERN VIRGINIA MEDICAL SCHOOL   (United States)

Author keywords

Free radicals; Kidney; Nitric oxide; Oxidative stress; Vitamins

Indexed keywords

ALPHA TOCOPHEROL; FREE RADICAL; GLYCOPROTEIN GP 91; INSULIN; ISOPROSTANE; LIGAND; LIPID PEROXIDE; MESSENGER RNA; NITRATE; NITRIC OXIDE; NITRITE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PIOGLITAZONE; PROTEIN P47; VITAMIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DIETARY INTAKE; DRUG EFFECT; ENDOTHELIUM; HYPERTENSION; INSULIN SYNTHESIS; KIDNEY CORTEX; KIDNEY MEDULLA; LIPID DIET; MALE; NERVE CELL; NONHUMAN; OBESITY; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; RAT STRAIN; SYSTOLIC BLOOD PRESSURE;

ANIMALS; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; DIET; HYPERTENSION; INSULIN; KIDNEY; MALE; NADPH OXIDASE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; OBESITY; OXIDATIVE STRESS; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, CYTOPLASMIC AND NUCLEAR; SODIUM; THIAZOLIDINEDIONES; TRANSCRIPTION FACTORS; VITAMIN E;

EID: 0346157985     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.HYP.0000103629.01745.59     Document Type: Article

References (34)

1. Mangelsdorf DJ, Thummel C, Beato M, Herrlich P, Schutz G, Umesono K, Blumberg B, Kastner P, Mark M, Chambon P. The nuclear receptor superfamily: the second decade. Cell. 1995;83:835-839.
2. Spiegelman BM. PPAR-γ: Adipogenic regulator and thiazolidinedione receptor. Diabetes. 1998;47:507-514.
3. Barroso I, Gurnell M, Crowley VE, Agostini M, Schwabe JW, Soos MA, Maslen GL, Williams TD, Lewis H, Schafer AJ, Chatterjee VK, O'Rahilly S. Dominant negative mutations in human PPARγ associated with severe insulin resistance, diabetes mellitus and hypertension. Nature. 1999;402:880-883.
4. Savage DB, Tan GD, Acerini CL, Jebb SA, Agostini M, Gurnell M, Williams RL, Umpleby AM, Thomas EL, Bell JD, Dixon AK, Dunne F, Boiani R, Cinti S, Vidal-Puig A, Karpe F, Chatterjee VK, O'Rahilly S. Human metabolic syndrome resulting from dominant-negative mutations in the nuclear receptor peroxisome proliferator-activated receptor-γ. Diabetes. 2003;52:910-917.
5. Forman BM, Chen J, Evans RM. The peroxisome proliferator-activated receptors: ligands and activators. Ann N Y Acad Sci. 1996;804:266-275.
6. Walker AB, Chattington PD, Buckingham RE, Williams G. The thiazolidinedione rosiglitazone (BRL-49653) lowers blood pressure and protects against impairment of endothelial function in Zucker fatty rats. Diabetes. 1999;48:1448-1453.
7. Uchida A, Nakata T, Hatta T, Kiyama M, Kawa T, Morimoto S, Miki S, Moriguchi J, Nakamura K, Fujita H, Itoh H, Sasaki S, Takeda K, Nakagawa M. Reduction of insulin resistance attenuates the development of hypertension in sucrose-fed SHR. Life Sci. 1997;61:455-464.
8. Yoshimoto T, Naruse M, Nishikawa M, Naruse K, Tanabe A, Seki T, Imaki T, Demura R, Aikawa E, Demura H. Antihypertensive and vasculo- and renoprotective effects of pioglitazone in genetically obese diabetic rats. Am J Physiol. 1997;272:E989-E996.
9. Fullert S, Schneider F, Haak E, Rau H, Badenhoop K, Lubben G, Usadel KH, Konrad T. Effects of pioglitazone in nondiabetic patients with arterial hypertension: a double-blind, placebo-controlled study. J Clin Endocrinol Metab. 2002;87:5503-5506.
10. Nicholas SB, Kawano Y, Wakino S, Collins AR, Hsueh WA. Expression and function of peroxisome proliferator-activated receptor-γ in mesangial cells. Hypertension. 2001;37:722-727.
11. Yang T, Michele DE, Park J, Smart AM, Lin Z, Brosius FC 3rd, Schnermann JB, Briggs JP. Expression of peroxisomal proliferator-activated receptors and retinoid X receptors in the kidney. Am J Physiol. 1999;277:F966-F973.
12. Guan Y, Zhang Y, Davis L, Breyer MD. Expression of peroxisome proliferator-activated receptors in urinary tract of rabbits and humans. Am J Physiol. 1997;273:F1013-F1022.
13. Guan Y, Zhang Y, Schneider A, Davis L, Breyer RM, Breyer MD. Peroxisome proliferator-activated receptor-γ activity is associated with renal microvasculature. Am J Physiol Renal Physiol. 2001;281: F1036-F1046.
14. Van Gaal LF, Vertommen J, De Leeuw IH. The in vitro oxidizability of lipoprotein particles in obese and non-obese subjects. Atherosclerosis. 1998;137(suppl):S39-S44.
15. Perticone F, Ceravolo R, Candigliota M, Ventura G, Iacopino S, Sinopoli F, Mattioli PL. Obesity and body far distribution induce endothelial dysfunction by oxidative stress: protective effect of vitamin C. Diabetes. 2001;50:159-165.
16. - and NO in the thick ascending limb. Hypertension. 2002;39:591-596.
17. - and NO. Am J Physiol Rental Physiol. 2000;279:F302-F308.
18. Pryor WA, Squadrito GL. The chemistry of peroxynitrite: a product from the reaction of nitric oxide with superoxide [see comments]. Am J Physiol. 1995;268:L699-L722.
19. Li N, Yi FX, Spurrier JL, Bobrowitz CA, Zou AP. Production of superoxide through NADH oxidase in thick ascending limb of Henle's loop in rat kidney. Am J Physiol Renal Physiol. 2002;282:F1111-F1119.
20. Chabrashvili T, Tojo A, Onozato ML, Kitiyakara C, Quinn MT, Fujita T, Welch WJ, Wilcox CS. Expression and cellular localization of classic NADPH oxidase subunits in the spontaneously hypertensive rat kidney. Hypertension. 2002;39:269-274.
21. 2+-superoxide dismutase and decrease p22phox message expressions in primary endothelial cells. Metabolism. 2001;50:3-11.
22. Von Knethen A, Brune B. Activation of peroxisome proliferator-activated receptor-γ by nitric oxide in monocytes/macrophages down-regulates p47phox and attenuates the respiratory burst. J Immunol. 2002;169:2619-2626.
23. Garg R, Kumbkarni Y, Aljada A, Mohanty P, Ghanim H, Hamouda W, Dandona P. Troglitazone reduces reactive oxygen species generation by leukocytes and lipid peroxidation and improves flow-mediated vasodilatation in obese subjects. Hypertension. 2000;36:430-435.
24. Dobrian AD, Davies MJ, Prewitt RL, Lauterio TJ. Development of hypertension in a rat model of diet-induced obesity. Hypertension. 2000;35:1009-1015.
25. Lauterio TJ, Barkan A, DeAngelo M, DeMott-Friberg R, Ramirez R. Plasma growth hormone secretion is impaired in obesity-prone rats before onset of diet-induced obesity. Am J Physiol. 1998;275:E6-E11.
26. Dobrian AD, Davies MJ, Schriver SD, Lauterio TJ, Prewitt RL. Oxidative stress in a rat model of obesity-induced hypertension. Hypertension. 2001;37:554-560.
27. Chomczynski P. A reagent for the single-step simultaneous isolation of RNA, DNA and proteins from cell and tissue samples. Biotechniques. 1993;15:532-534, 536-537.
28. Dobrian AD, Schriver SD, Prewitt RL. Role of angiotensin II and free radicals in blood pressure regulation in a rat model of renal hypertension. Hypertension. 2001;38:361-366.
29. Lauterio TJ, Davies MJ, DeAngelo M, Peyser M, Lee J. Neuropeptide Y expression and endogenous leptin concentrations in a dietary model of obesity. Obes Res. 1999;7:498-505.
30. Vidal-Puig A, Jimenez-Linan M, Lowell BB, Hamann A, Hu E, Spiegelman B, Flier JS, Moller DE. Regulation of PPARγ gene expression by nutrition and obesity in rodents. J Clin Invest. 1996;97:2553-2561.
31. Cantley LC. The phosphoinositide 3-kinase pathway. Science. 2002;296:1655-1657.
32. Watanabe M, Inukai K, Katagiri H, Awata T, Oka Y, Katayama S. Regulation of PPARγ transcriptional activity in 3T3-L1 adipocytes. Biochem Biophys Res Commun. 2003;300:429-436.
33. Makino A, Skelton MM, Zou AP, Roman RJ, Cowley AW Jr. Increased renal medullary oxidative stress produces hypertension. Hypertension. 2002;39:667-672.
34. Shiojiri T, Wada K, Nakajima A, Katayama K, Shibuya A, Kudo C, Kadowaki T, Mayumi T, Yura Y, Kamisaki Y. PPARγ ligands inhibit nitrotyrosine formation and inflammatory mediator expressions in adjuvant-induced rheumatoid arthritis mice. Eur J Pharmacol. 2002;448:231-238.